Business Wire

Stilla Launches Access Program for Industry’s First Six-Color Digital PCR System

28.7.2021 19:26:00 EEST | Business Wire | Press release

Share

Stilla Technologies, the company innovating the next generation of digital PCR solutions for life science research and molecular diagnostics, is pleased to announce the launch of its 6-Color Digital PCR Access Program which enables early access to the industry’s first Digital PCR system featuring six fluorescent channels for providing the highest multiplexing and detection capacity available on the market today. This represents a broad portfolio expansion of the Company’s original three-color naica® system and includes reagents and digital PCR consumables, automated analytical instrumentation, and turnkey visualization software. The commercial launch of the six-color naica® system is scheduled for Fall 2021.

“There is undeniable value in detecting and quantifying multiple mutations, viruses and biomarkers from a single sample. The cost versus depth tradeoffs of NGS make it impractical for the routine testing of many samples per day, while multiplex qPCR lacks the precise quantitation and exquisite sensitivity offered by digital PCR,” said Matthew Grow, PhD, Vice President Global Marketing and Commercial Operations, Stilla Technologies. “Stilla’s new six-color product offers biomedical researchers and clinicians an unprecedented level of digital multiplexing with no compromises in applications ranging from ultra-sensitive liquid biopsies and SARS-CoV-2 variant detection where rare targets are found in large sample volumes, to the absolute quantitation needed in testing such as DNA methylation, viral titering, and disease-related gene amplifications.”

Stilla is offering scientists an opportunity to experience the power and flexibility of 6-color Digital PCR by providing a range of options to drive their evaluations, including both hands-on or remote demonstrations of the naica® system. Researchers with existing qPCR or dPCR assays may request that their assays be tested using their own samples or opt to use an available 6-color assay from Stilla. On-site demos are available on a first come, first served basis.

“As biology becomes more and more complex, researchers increasingly require next-gen tools to unlock next-gen biological breakthroughs,” said Rémi Dangla, PhD, Cofounder and Chief Technology Officer, Stilla Technologies. “Stilla’s six-color Digital PCR aligns with the complexity of biological systems and provides scientists with a superior tool for accelerating biological insights to advance their research and discovery.”

Earlier this month, the United States District Court for the District of Massachusetts issued a settlement order of dismissal on a patent infringement suit brought against Stilla by Bio-Rad Laboratories. Under the terms of the agreement, Stilla Technologies will have access to certain Intellectual Property rights from Bio-Rad in the field of digital PCR, supporting Stilla’s strategy for full deployment of its dPCR product and services in key markets.

“We are highly encouraged by this outcome which demonstrates Stilla’s steadfast commitment to upholding integrity in all our operations while advancing technological innovation to accelerate research and improve human health,” added Dr. Dangla.

For more information on the Crystal Digital PCR™ Access Program, email demo@stillatechnologies.com or sign up online at: https://www.stillatechnologies.com/6-color-dpcr/.

About Stilla Technologies

Stilla Technologies is the global life sciences company providing a groundbreaking Crystal Digital PCR™ (dPCR) solution that enables researchers and clinicians to accelerate development of advanced genetic testing and molecular biology assays for a wide range of applications, including cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection, and food and environmental testing. Stilla aims to make dPCR a lab commodity for life sciences research, therapeutics and omics with its flexible naica® system, which incorporates proprietary, cutting–edge microfluidic innovations in addition to unsurpassed customer service and application support. To learn more visit www.stillatechnologies.com and connect with Stilla on social media Twitter, LinkedIn and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heidi Creighton
heidi.creighton@stillatechnologies.com
Mobile/Text: 978-302-1198

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 12:21:00 EEST | Press release

The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrate that personalising treatment decisions for patients with early-stage (stage II to IIIA) HER2-positive BC using the HER2DX genomic diagnostic assay can improve pat

The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AI7.5.2026 11:00:00 EEST | Press release

The AI Summit London today unveiled its keynote speaker line-up for the event’s 10th anniversary edition, bringing together senior leaders, technologists and policymakers from across the globe. The 2026 programme will explore the transformative power of artificial intelligence across sectors including government, enterprise, healthcare, finance and AI infrastructure. Speakers from NVIDIA, Amazon Web Services, Virgin Atlantic, AstraZeneca, the Tony Blair Institute for Global Change and JPMorgan Chase will explore AI deployment, governance, infrastructure and customer transformation across major industries. Further, Jim Carter, Director General Commercial and Industry at the Ministry of Defence, Ollie Ilott, Interim Director General, Emerging Technology and AI, UK Government, and Sasha Rubel, Head of AI/Generative AI Policy, EMEA, Amazon Web Services will lead the “AI Sovereignty – Possibility or Pipe Dream for Europe?” panel, debating whether Europe can realistically compete in the glob

MOVIVA ® launch spotlight at ESGE Days 20267.5.2026 10:58:00 EEST | Press release

During its 175th anniversary year, Erbe Elektromedizin GmbH highlights its continued commitment to healthcare innovation with the launch of MOVIVA®, a minimally invasive solution for gastric mucosal ablation (GMA) in endoscopic obesity therapy. MOVIVA® will be the central focus of Erbe’s activities at ESGE Days in Milan, 14–16 May 2026. Physicians can explore the technology in the hands-on area and attend a dedicated symposium. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507842222/en/ How GMA with MOVIVA® works “Obesity continues to rise worldwide, and many patients still face a gap between lifestyle interventions, pharmacotherapy, and bariatric surgery. Endoscopic approaches are emerging as additional treatment options. With MOVIVA®, we aim to support physicians in bringing this innovative treatment option into clinical practice and expanding access to minimally invasive obesity therapies.” Marcus Felstead, Chief Comm

Resilience Takes Center Stage as Europe’s LEED Community Gathers in Milan for GBCI Europe Circle 20267.5.2026 10:57:00 EEST | Press release

Green Business Certification Inc. Europe (GBCI), is hosting Circle 2026, the annual flagship event of the European LEED community, taking place in Milan from May 6–8 and marking its fifth anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506692329/en/ Porta Nuova, Milan - LEED v4.1 Communities: Existing, Gold certification. Photo courtesy of COIMA. At the center of discussions is LEED v5, the latest version of the world’s most widely used green building rating system, as a bridge to EU Taxonomy alignment - a critical priority for the European market, where regulatory pressure and investor demand are accelerating the integration of certification, finance, and ESG reporting. GBCI Europe Impact Report 2026: European Real Estate Shifts from Sustainability to Risk Management As part of the main conference program, Peter Templeton, President and CEO of USGBC and GBCI will present the GBCI Europe Impact Report 2026, ba

Criteo Selects Navan to Modernize Global Travel Management7.5.2026 10:00:00 EEST | Press release

Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/ Global commerce intelligence platform delivers high employee satisfaction with Navan Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting. “We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Glickman, Chief Financial Officer at Criteo. “Our goal with Navan was to improve the use

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye